Crinetics Pharmaceuticals, Inc. 4

Tobin Schilke, the Chief Financial & Infrastructure Officer of Crinetics Pharmaceuticals, Inc., received 471 shares of common stock via a restricted stock unit award on August 20, 2026.

On August 20, 2026, Tobin Schilke, Chief Financial & Infrastructure Officer of Crinetics Pharmaceuticals, Inc., received an equity compensation grant of 471 shares of common stock in the form of restricted stock units, recorded on the Form 4 as an acquisition at zero cost. These RSUs represent the right to receive shares of the issuer’s common stock with 25% of the units vesting annually beginning on September 1, 2027, indicating a multi‑year retention incentive. Following this award, Schilke’s direct ownership increased to 79,427 shares, which total includes 835 shares previously acquired under the company’s Employee Stock Purchase Plan. No open‑market purchases or sales of shares were reported in this filing, and the transaction appears to be a routine equity compensation grant rather than a discretionary trade.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-058664

Alert Tier

5